Letters sent to healthcare professionals in June 2016

In June 2016, a letter was sent to healthcare professionals about Thalidomide Celgene.

From:
Medicines and Healthcare products Regulatory Agency
Published
18 July 2016
Therapeutic area:
Cancer

On 20 June 2016, a letter was sent to healthcare professionals about Thalidomide Celgene: risks of viral reactivation and pulmonary hypertension associated with Thalidomide Celgene.

Updates to this page

Published 18 July 2016